Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data ; volume:41 ; number:12 ; day:28 ; month:10 ; year:2024 ; pages:4581-4590 ; date:12.2024
Advances in therapy ; 41, Heft 12 (28.10.2024), 4581-4590, 12.2024
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-03023-4
- URN
-
urn:nbn:de:101:1-2501272121345.727301766811
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chaudhuri, Nazia
- Azuma, Arata
- Sroka-Saidi, Kamila
- Erhardt, Elvira
- Ritter, Ivana
- Harari, Sergio
- SpringerLink (Online service)
Other Objects (12)
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases